| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/06/2002 | WO2002043762A2 Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| 06/06/2002 | WO2002043759A2 Method and composition for modulating bone growth |
| 06/06/2002 | WO2002043758A2 Uses of mammalian genes and related reagents |
| 06/06/2002 | WO2002043755A1 Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing processes |
| 06/06/2002 | WO2002043754A1 Proteins binding hcv and their medical, diagnostic and purification use |
| 06/06/2002 | WO2002043753A1 Remedies for chronic hepatitis b |
| 06/06/2002 | WO2002043752A1 Interferon therapeutic effect-potentiating agents |
| 06/06/2002 | WO2002043751A1 Use of insulin containing composition for wound treatment |
| 06/06/2002 | WO2002043750A2 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| 06/06/2002 | WO2002043749A1 Inducing expression of heat shock proteins |
| 06/06/2002 | WO2002043748A1 Methods of treatment comprising administration of substance p |
| 06/06/2002 | WO2002043747A2 Modulation of cell growth by inhibiting binding of kringle 2 domain of plasminogen |
| 06/06/2002 | WO2002043746A2 Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
| 06/06/2002 | WO2002043745A2 Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma |
| 06/06/2002 | WO2002043741A2 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 06/06/2002 | WO2002043730A1 Use of mdr-1 inducers for treating or preventing diseases |
| 06/06/2002 | WO2002043709A1 Method for producing preparation containing bioactive substance |
| 06/06/2002 | WO2002043703A1 Powdery preparations and proecss for producing the same |
| 06/06/2002 | WO2002043699A2 Preparation of large liposomes by infusion into peg |
| 06/06/2002 | WO2002043695A2 Stable, aerosolizable suspensions of proteins (e.g. insulin, dnase) in ethanol |
| 06/06/2002 | WO2002043665A2 Ahf associated dispersion system and method for preparation |
| 06/06/2002 | WO2002043654A2 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions |
| 06/06/2002 | WO2002043647A2 Oncolytic virus |
| 06/06/2002 | WO2002043578A2 Determination of risk and treatment of complications of prematurity |
| 06/06/2002 | WO2002043572A2 Erythropoietin and erythropoietin receptor expression in human cancer |
| 06/06/2002 | WO2002043570A2 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES |
| 06/06/2002 | WO2002043567A2 A method of treating cancer |
| 06/06/2002 | WO2002043566A2 Devices and methods for treating low blood sugar levels |
| 06/06/2002 | WO2002043507A2 Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| 06/06/2002 | WO2002028895A3 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 06/06/2002 | WO2002024148A3 Method or treatment of tumors using transforming growth factor-alpha |
| 06/06/2002 | WO2002024144A3 Use of transcription factors for treating inflammation and other diseases |
| 06/06/2002 | WO2002018437A3 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 06/06/2002 | WO2002005843A3 Human rrp sequences and methods of use |
| 06/06/2002 | WO2002003914A3 Improved thyroid hormone formulations |
| 06/06/2002 | WO2002002606A3 Immunisation against chlamydia pneumoniae |
| 06/06/2002 | WO2002000906A3 Replication deficient adenoviral tnf vector |
| 06/06/2002 | WO2002000261A3 Surfactant-containing formulations for extended release of somatotropin |
| 06/06/2002 | WO2001098340A3 Regulation of human mast cell protease 6-like enzyme |
| 06/06/2002 | WO2001096542A3 A human aminotransferase (23680) and uses thereof |
| 06/06/2002 | WO2001096538A3 Regulation of human transmembrane serine protease |
| 06/06/2002 | WO2001094293A3 Benzamide ligands for the thyroid receptor |
| 06/06/2002 | WO2001092524A3 Myosin-like gene expressed in human heart and muscle |
| 06/06/2002 | WO2001092305A3 Mammalian transforming growth factor beta-10 |
| 06/06/2002 | WO2001090360A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001090331A3 C1 bacteriophage lytic system |
| 06/06/2002 | WO2001088116A9 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 06/06/2002 | WO2001087238A3 Induction of apoptosis and cell growth inhibition by protein 4.33 |
| 06/06/2002 | WO2001079466A3 Regulation of human epithin-like serine protease |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |
| 06/06/2002 | WO2001074997A3 Novel polypeptide - a human cannabis alcohol receptor protein 11 and polynucleotide encoding it |
| 06/06/2002 | WO2001074768A3 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 06/06/2002 | WO2001074128A3 A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide |
| 06/06/2002 | WO2001072784A3 Peptides binding to non-acetylated h3 and h4 histones for cancer therapy |
| 06/06/2002 | WO2001072323A3 Use of insulin for the treatment of cartilagenous disorders |
| 06/06/2002 | WO2001068849A3 Human ion channels |
| 06/06/2002 | WO2001064907A3 Lipid metabolism enzymes |
| 06/06/2002 | WO2001064884A3 G12l, a gene associated with the thermal response |
| 06/06/2002 | WO2001049324A3 Novel colloid synthetic vectors for gene therapy |
| 06/06/2002 | WO2001042225A8 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 06/06/2002 | WO2001040259A8 Monkey orexin 1 receptor |
| 06/06/2002 | WO2001036645A3 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 06/06/2002 | WO2001031014A3 G protein-coupled receptors expressed in human brain |
| 06/06/2002 | WO2001012232A8 Process to make a sustained release formulation |
| 06/06/2002 | WO2001012168A3 Antiviral pharmaceutical compositions containing iron chelators |
| 06/06/2002 | WO2001002012A8 Remedies for drug-resistant hypercalcemia |
| 06/06/2002 | WO2001000306A9 Preparation of a therapeutic composition |
| 06/06/2002 | WO2000024782A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 06/06/2002 | WO2000022430A3 Neisseria genomic sequences and methods of their use |
| 06/06/2002 | US20020069422 Proteins for use in the treatment of trypanosome infection, cancer, inflammation and immunological defects |
| 06/06/2002 | US20020068825 Polypeptide for use in the treatment of nervous system disorders |
| 06/06/2002 | US20020068824 Membrane protein for use in the treatnment of diabetes, hypotension, endocrine defects |
| 06/06/2002 | US20020068823 33877 and 47179, novel human glycosyltransferase family members and uses thereof |
| 06/06/2002 | US20020068820 Hpv-specific oligonucleotides |
| 06/06/2002 | US20020068817 Dictyocaulus viviparus antigen for diagnosing lungworm infestation and for vaccination |
| 06/06/2002 | US20020068815 Nucleotide sequence coding receptor proteins for use in the treatment of urogential disorders |
| 06/06/2002 | US20020068814 Vasoactive peptide for use in the treatment of inflammtion, congestive heart failure, migraines, diabetes and sepsis |
| 06/06/2002 | US20020068813 Sulfated CCR5 peptides for HIV-1 infection |
| 06/06/2002 | US20020068761 Administering a therapeutically effective amount of a neutral 3:1 gallium complex of a 3- hydroxy-4-pyrone derivative to a patient infected by a prokaryote of geneus mycobacterium |
| 06/06/2002 | US20020068757 Administering biflavanoid selected from robustaflavone, amentoflavone, agathisflavone, volkensiflavone, rhusflavanone, succedaneaflavanone, morelloflavone etc. and atleast one antiviral agent to treat viral infection |
| 06/06/2002 | US20020068749 Synergist mixture of KNI-272 and one compound selected from the group consisting of Saquinavir, Ritonavir, Indinavir, and Nelfinavir |
| 06/06/2002 | US20020068747 Inhibitors of prenyl-protein transferase |
| 06/06/2002 | US20020068741 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 06/06/2002 | US20020068719 Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
| 06/06/2002 | US20020068716 Pituitary-tumor-transforming-gene (PTTG) polypeptide expressed by pituitary tumor cells, which binds anti-PTTG antibody. |
| 06/06/2002 | US20020068713 Genetic engineering of vascular grafts to resist disease |
| 06/06/2002 | US20020068711 Arrest of proliferation of highly glycolytic tumors |
| 06/06/2002 | US20020068709 Modulating expression of a gene involved in malignant cell growth, comprising contacting with an oligonucleotide that comprises one or more locked nucleic acid units |
| 06/06/2002 | US20020068706 Inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, can be used to control proliferation and/or differentiation of cells |
| 06/06/2002 | US20020068703 Modulating the interaction of immune complexes with tissue Fc receptors by introducing an inhibitor of an endogenous kinase |
| 06/06/2002 | US20020068702 Containing eleven amino acid residues |
| 06/06/2002 | US20020068700 Treatment of heart failure with growth hormone |
| 06/06/2002 | US20020068699 Clostridial toxin derivatives and methods for treating pain |
| 06/06/2002 | US20020068697 Peptides blocking vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 06/06/2002 | US20020068696 Modulating proliferation and apoptotic state of cells using agents that modulate the expression and/or activity of TRADE family polypeptides. |
| 06/06/2002 | US20020068695 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 06/06/2002 | US20020068694 Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B |
| 06/06/2002 | US20020068693 Non-aqueous surfactant-containing formulations for extended release of somatotropin |
| 06/06/2002 | US20020068690 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased |